BioStock: Evaxion Biotech publishes EVX-01 data in scientific journal OncoImmunology

This past decade has seen the rise of immunotherapies for the treatment of cancer, in many ways revolutionising this enormous treatment field. Danish Evaxion Biotech aims at pushing this development even further with its AI-powered personalised approach. The company recently published results from an ongoing phase I/IIa clinical study with lead drug candidate EVX-01 in the open access, peer-reviewed clinical journal OncoImmunology.

 Read the full article at biostock.se:

https://www.biostock.se/en/2022/02/evaxion-biotech-publishes-evx-01-data-in-scientific-journal-oncoimmunology/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se